Abstract:Objective To explore hypermethylation of RARβ2, GSTP1 and DAPK gene in prostate cancer tissues, and to explore its correlation with clinicopathological features of prostate cancer and its diagnostic value. Methods Hypermethylation of RARe2, GSTP1 and DAPK gene was detected by nested methylation-specific PCR (NMSP) in 57 prostate cancer (PCa) tissues and 35 benign prostate hyperplasia (BPH) tissues. The correlation between hypermethylation and clinicopathological features of prostate cancer and its diagnostic value were analyzed. Results The hypermethylation frequencies of RARβ2, GSTP1 and DAPK gene in PCa were significantly higher than those in BPH (RARβ2: 52.6% vs. 0% GSTP1: 61.4% vs. 2.9%;DAPK: 43.9% vs. 8.6%;all P<0.01). The methylation rate of RARβ2 gene was directly correlated with distinct Gleason scores and clinical stage (4～7 score vs. 8～10 score: 34.8% vs. 64.7%;stage B, C vs. stage D: 37.0% vs. 66.7%;x2=4.927 and 5.004, P=0.026 and 0.025). The methylation rate of GSTP1 gene was significantly different in patients with different Gleason scores (4～7 score vs. 8～10 score: 43.5% vs. 73.5%;x2 =11.530, P=0.001), but had no difference in patients with distinct clinical stage (stage B, C vs. stage D: 51.9% vs. 70.0%;x2=1.975, P=0.16) . There was no difference in DAPK gene methylation rate among patients with different Gleason scores and distinct clinical stage (4 ～7 score vs. 8～10 score: 39.1% vs. 50.0%;stage B, C vs. stage D: 33.3% vs. 53.3%;x2= 1.290 and 2.309, both P～0.05). GSTP1 gene showed the highest sensitivity of 61.4% (35/57)with specificity of 97.1%(34/35), while RARβ2 gene had the highest specificity of 100% (35/35) with the sensitivity of 52.6% (30/57). The sensitivity and specificity of DAPK gene were 43.9% and 91.4% (25/57 and 32/35), respeetively. When the hypermethylation of RARβ2, GSTP1 and DAPK gene were detected together, the diagnostic sensitivity was increased, but the specificity was decreased. Conclusions The aberrant methylation of RARβ2, GSTP1 and DAPK gene is correlated with tumorigenesis and progression of prostate cancer, which may be used as an effective diagnostic marker for prostate cancer.

[Diagnostic Value of BRCA1 and P16 Gene Methylation in Sporadic Breast Cancer].

Detection of aberrant methylation of RARβ2, GSTP1 and DAPK gene in prostate cancer and its clinical significance

Clinical signiifcance of BRCA1, GSTP1 and MGMT gene methylation status in breast cancer

Methylation of p16 Gene in the Invasive Ductal Bbreast Cancer

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

Effects of the Methylation Levels for the Breast Cancer Associated Genes BCSG1 and BRCA1 on Cellular Proliferation and Migration

The Prognostic Value Of P16 Hypermethylation In Cancer: A Meta-Analysis

Diagnostic value of serum P 16 gene promoter methylation in gastric cancer : a meta-analysis

DNA Methylation Profiles and Their Diagnostic Utility in BC

Brca1 Promoter Methylation Associated With Poor Survival In Chinese Patients With Sporadic Breast Cancer

[Promoter methylation profile in breast cancer]

[Detection of Free Tumor-Related DNA in the Serum of Breast Cancer Patients].

Detection of P16 Gene Methylation by Methylation-Specific PCR and Its Clinical Significance in Lung Cancer

Detection of BRCA1,CDH1,DKK1 and SFRP1 Methylation in Peripheral Blood Cells of Patients with Metastatic Breast Cancer

Study of P16 Tumor Suppressor Gene with Methylation-Specific PCR

Study on the relevancy of p16 gene methylation and the malignant change level of the cervix

Detection of aberrant p16 methylation in the serum of colorectal cancer patients

Potential Diagnostic and Prognostic Values of Detecting Promoter Hypermethylation in the Serum of Patients with Gastric Cancer

P16 Promoter Hypermethylation is Associated with Increased Breast Cancer Risk

Aberrant Methylation of CpG Island in 5'promoter Region of P16 Gene and Its Role in Diagnosis of Pancreatic Cancer

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer